Area of research
Oncology · Molecular Biology
Research interest
Research interests include Angiogenesis and VEGF in Cancer, Advanced Breast Cancer Therapies, Cancer, Hypoxia, and Metabolism, and Cancer Cells and Metastasis.
Apoptotic body-encapsulated zinc-doped Salvia miltiorrhiza carbon dots trigger PANoptosis for targeted therapy of hepatocellular carcinoma
Suppression of Sepsis Cytokine Storm by <i>Escherichia Coli</i> Cell Wall‐Derived Carbon Dots
Extrachromosomal DNA biogenesis is dependent on DNA looping and religation by YY1-Lig3-PARylation complex
Rbfox3 Promotes Transformation of MDSC‐Like Tumor Cells to Shape Immunosuppressive Microenvironment
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
Glycated ECM Derived Carbon Dots Inhibit Tumor Vasculogenic Mimicry by Disrupting RAGE Nuclear Translocation and Its Interaction With HMGB1
<scp>SYHA1813</scp> , A <scp>VEGFR</scp> and <scp>CSF1R</scp> Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study
Biomimetic carbon nanopolymers ANM-NPs act on mannose receptors and complement receptors to promote tumor antigen presentation
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases
EGR3 Inhibits Tumor Progression by Inducing Schwann Cell‐Like Differentiation
WRN Nuclease‐Mediated EcDNA Clearance Enhances Antitumor Therapy in Conjunction with Trehalose Dimycolate/Mesoporous Silica Nanoparticles
Correction: Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin
A non-retinol RAR-γ selective agonist-tectorigenin can effectively inhibit the UV-induced skin damage
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma
HSF4/COIL complex‐dependent R‐loop mediates ultraviolet‐induced inflammatory skin injury
Abstract PD11-10: PD11-10 Efficacy, Safety, and Tolerability of KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in combination with Nab-paclitaxel in Metastatic Triple-negative Breast Cancer (mTNBC):Final results of the Phase II trial
Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.
LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial
A non‐retinol retinoic acid receptor‐γ (RAR‐γ/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A‐induced skin damage
LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial
Abstract GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial of pyrotinib versus lapatinib in combination with capecitabine in patients with HER2-positive metastatic breast cancer
Chrysin targets myeloid‐derived suppressor cells and enhances tumour response to anti‐PD‐1 immunotherapy
Abstract GS1-06: A randomized control phase III trial of entinostat, a once weekly, class I selective histone deacetylase inhibitor, in combination with exemestane in patients with hormone receptor positive advanced breast cancer
196P Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)
Abstract PD8-05: Overall survival (OS) results from the phase III PHENIX trial of HER2+ metastatic breast cancer treated with pyrotinib plus capecitabine
Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor
Potential type 2 diabetes mellitus drug HMPA promotes short-chain fatty acid production by improving carbon catabolite repression effect of gut microbiota.